6.29

6.79% 0.40

Bausch Health Companies Inc (BHC)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Bausch Health Companies Inc stock is traded at $6.29, with a volume of 1.34M. It is up +6.79% in the last 24 hours and up +10.93% over the past month. Bausch Health Companies Inc is a world-wide specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum of its revenue from the Bausch + Lomb segment.

Previous Close:

$5.89

Open:

$5.95

24h Volume:

1.34M

Relative Volume:

0.69

Market Cap:

$2.35B

Revenue:

$10.53B

Net Income/Loss:

$-1.23B

P/E Ratio:

-1.9378

EPS:

-3.246

Net Cash Flow:

$949.99M

1W Performance:

+4.14%

1M Performance:

+10.93%

6M Performance:

+9.58%

1Y Performance:

+4.49%

1-Day Range:

$5.95

$6.35

1-Week Range:

$5.732

$6.345

52-Week Range:

$4.33

$8.00

Bausch Health Companies Inc Stock (BHC) Company Profile

Name

Bausch Health Companies Inc

Sector

Healthcare (1051)

Industry

Drug Manufacturers - Specialty & Generic (84)

Phone

514-744-6792

Address

2150 ST. ELZEAR BLVD. WEST, QUEBEC, QC

Employee

20,300

Twitter

Next Earnings Date

2026-10-28

Latest SEC Filings

BHC's Discussions on Twitter

Compare BHC vs TAK, TEVA, HLN, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BHC Bausch Health Companies Inc	6.29	2.35B	10.53B	-1.23B	949.99M	-3.246
TAK Takeda Pharmaceutical Co Adr	19.64	62.73B	29.91B	1.30B	3.49B	0.4056
TEVA Teva Pharmaceutical Industries Ltd Adr	41.26	48.12B	17.53B	1.58B	444.18M	1.3457
HLN Haleon Plc Adr	9.965	43.82B	14.54B	2.22B	2.58B	0.4871
ZTS Zoetis Inc	78.69	32.52B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	549.00	23.55B	3.17B	1.29B	1.01B	27.09

Bausch Health Companies Inc Stock (BHC) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-09-25	Initiated	Barclays	Equal Weight
Aug-02-24	Downgrade	Piper Sandler	Neutral → Underweight
Jul-10-24	Initiated	Raymond James	Mkt Perform
Sep-20-23	Upgrade	Jefferies	Hold → Buy
Jun-16-23	Downgrade	TD Cowen	Outperform → Market Perform
Jul-29-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-29-22	Downgrade	Truist	Buy → Hold
Jul-28-22	Downgrade	JP Morgan	Overweight → Neutral
Jun-13-22	Resumed	JP Morgan	Overweight
Mar-24-21	Downgrade	BofA Securities	Neutral → Underperform
Feb-17-21	Upgrade	RBC Capital Mkts	Sector Perform → Outperform
Jan-22-21	Downgrade	Piper Sandler	Overweight → Neutral
Sep-17-20	Upgrade	BofA Securities	Underperform → Neutral
Aug-24-20	Reiterated	H.C. Wainwright	Buy
Jun-17-20	Reiterated	H.C. Wainwright	Buy
Apr-24-20	Initiated	Citigroup	Buy
Apr-02-20	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-29-20	Downgrade	Wolfe Research	Outperform → Peer Perform
Jan-22-20	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-12-19	Upgrade	JP Morgan	Neutral → Overweight
Dec-02-19	Initiated	Goldman	Neutral
Oct-25-19	Initiated	Cowen	Outperform
Sep-12-19	Initiated	Guggenheim	Buy
Aug-15-19	Upgrade	TD Securities	Hold → Buy
Jul-19-19	Initiated	Wolfe Research	Outperform
Jun-11-19	Resumed	Barclays	Overweight
May-13-19	Upgrade	JP Morgan	Underweight → Neutral
Mar-20-19	Initiated	SunTrust	Buy
Jan-02-19	Upgrade	Piper Jaffray	Neutral → Overweight
Nov-05-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Sep-13-18	Upgrade	Piper Jaffray	Underweight → Neutral

View All

Bausch Health Companies Inc Stock (BHC) Latest News

Oct 12, 2026

Bausch + Lomb CEO Saunders departs, Chairman Appio named interim chief - Reuters

Oct 12, 2026

Thomas J. Appio Named Interim CEO of Bausch + Lomb as Brent Saunders Departs - VisionMonday.com

Oct 12, 2026

What Could Bausch Health (TSX:BHC) Reveal in Its Next Results? - Kalkine Media

Oct 12, 2026

Bausch + Lomb CEO Saunders steps down, Chairman Appio appointed interim chief - The Mighty 790 KFGO

Oct 12, 2026

Bausch Health study shows improved cirrhosis care adherence By Investing.com - Investing.com Canada

Oct 12, 2026

Bausch Health study shows modest gains in cirrhosis care adherence - StreetInsider

Oct 12, 2026

Six-Month Pilot Study Demonstrates Improved Guideline Adherence Following Implementation of Standardized Cirrhosis Clinical Pathway - PR Newswire

Oct 12, 2026

Bausch + Lomb Names Thomas J. Appio Interim CEO - www.tokenpost.com

Oct 12, 2026

Bausch + Lomb names Appio interim CEO as Saunders departs - StreetInsider

Oct 12, 2026

Bausch + Lomb and Bausch Health Announce Appointment of Thomas J. Appio as Interim Bausch + Lomb CEO, Expect to Raise Full-Year 2026 Guidance - The Globe and Mail

Oct 12, 2026

Oct 10, 2026